The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2007, 179, 7316-7324
Copyright © 2007 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quandt, D.
Right arrow Articles by Brunner-Weinzierl, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quandt, D.
Right arrow Articles by Brunner-Weinzierl, M. C.

A New Role of CTLA-4 on B Cells in Thymus-Dependent Immune Responses In Vivo1

Dagmar Quandt*,{dagger}, Holger Hoff*,{dagger},{ddagger}, Marion Rudolph*,{dagger},{ddagger}, Simon Fillatreau* and Monika C. Brunner-Weinzierl2,*,{dagger},{ddagger}

* Deutsches Rheuma-Forschungszentrum, Berlin; {dagger} Klinik für Innere Medizin mit Schwerpunkt Rheumatologie und Klinischer Immunologie, Charité-Universitätsmedizin, Berlin, Germany; and {ddagger} Klinik für Pädiatrie, Otto von Guericke Universität Magdeburg, Magdeburg, Germany


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The expression of CTLA-4 (CD152) on the cell surface of B cells and its consequences for the humoral immune response in vivo are unknown. We investigated the expression of CTLA-4 mRNA and protein in B cells in T cell-independent or -dependent ways. B cells in the presence of Ag-stimulated Th2 cells expressed mRNA of CTLA-4 and up-regulated intracellular CTLA-4 protein. Using a liposome-enhanced staining technique, we show for the first time, that surface CTLA-4 protein is expressed by 11–15% of B cells in a T cell-dependent culture system. To dissect the role of CTLA-4 on B cells in vivo, we used bone marrow chimeric mice in which only B cells were CTLA-4 deficient. These mice showed that early B cell development and homeostasis is not influenced by CTLA-4 deficiency of B cells. Ag-specific responses after immunization of the chimeric mice revealed elevated levels of IgM Abs in mice deficient for B cell CTLA-4. We propose that CTLA-4 signals on B cells determine the early fate of B cells in thymus-dependent immune responses.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
B cells are essential for the adaptive immune response, not only through the production and secretion of Abs, but also by the secretion of cytokines and their capacity to present Ag to T cells. B cells can either be effector cells in a thymus-independent response, when they are activated by, e.g., bacterial polysaccharides, which occurs mostly without T cell help (1). In contrast, in a thymus- dependent (TD)3 response, B cells can be effector cells with the help of T cells, when both cell types recognize Ags from the same pathogen and form cognate B-T cell interactions (2, 3).

After cross-linking of the BCR in either thymus-independent or TD immune responses, a second signal is needed for B cell activation either coming from the Ag itself via concomitant cross-linking of TLRs and/or complement receptors or the second signal is provided by T cells in TD responses. Such costimulatory signals for B cells in TD responses are delivered via CD40, CD30, and the members of the B7 superfamily when B cells present the cognate Ag on MHC class II (MHC II) to T cells (4, 5, 6). There are two main classes of costimulatory molecules, the Ig superfamily and the TNF/TNFR family with receptor/ligand expression on APCs and lymphocytes (4, 7, 8). The primary members of the Ig superfamily are the receptors CD28 and its homolog CTLA-4 on T cells recognizing the same ligands B7-1/B7-2 (CD80/CD86) on APCs. CTLA-4 (CD152) is a 33- to 37-kDa transmembrane glycoprotein which is known to be the major inhibitory molecule for T cell responses (4, 9, 10). CTLA-4 has also been shown to induce resistance against apoptosis by down-regulation of Fas and Fas ligand, up-regulation of Bcl-2, and activation of PI3K (11). Thus, besides competing with CD28 for its ligand B7, it has become clear that CTLA-4 can indeed initiate signaling pathways in T cells (9). In activated T cells, CTLA-4 molecules are stored in intracellular vesicles and remain there for >1 wk (12). Vesicles containing CTLA-4 are mobilized toward the sites of Ag receptor engagement and probably expressed at the immunological synapse (13, 14). CTLA-4 surface expression is tightly controlled and on most T cells only temporarily expressed at the cell surface. Unlike intracellular CTLA-4, surface CTLA-4 is restricted to a fraction of activated T cells (11, 12).

The cell type-specific expression of the costimulatory molecules has been challenged in the recent years. There is evidence from in vitro and in vivo data that B7-1 and B7-2 ligands are not only expressed on APCs, but also on T cells (15, 16, 17). This B7 expression on T cells can regulate alloresponses via CTLA-4 by T:T contact (18). The importance of B7 expression on T cells is further emphasized by the fact that transfer of B7-deficient T cells in contrast to B7-competent T cells causes severe disorders in Rag–/– mice, which cannot be controlled by CD4+CD25+ regulatory T cells (19). Additionally, there are data for CD28 expression on EBV-infected B cells as well as on plasma cells (20, 21, 22). Because it is technically difficult to identify functional surface CTLA-4 expression, only suggestive evidence with conflicting results about expression and function on B cells has been demonstrated so far (23, 24, 25, 26, 27). The idea about CTLA-4 expression on B cells is intriguing, because inhibitory receptors on B cells, such as Fc{gamma}RII, CD22, CD72, PD-1, PIR-B, and BTLA (28, 29, 30), are well known and some of them are also expressed on T cells and B cells. Furthermore, the phenotype of CTLA-4–/– mice with an elevation of B7-2, Fas, and CD5 expression, as well as dramatically enhanced Ab production by B cells might already point to the existence of CTLA-4 in B cells (31, 32).

Our aim was to unambiguously identify surface CTLA-4 expression on B cells, establish conditions for its expression, and determine its function in B cell development and differentiation in vivo. Since surface CTLA-4 is expressed only at low levels on the cell surface and technically difficult to detect by conventional cytometric analysis, we clarified the expression on the surface of B cells using a unique, enhanced staining technique with fluorescein-filled liposomes (11, 12, 33). We identified surface CTLA-4-expressing B cells with a peak expression 48–72 h after stimulation in T cell-dependent culture systems. The CTLA-4 mRNA in highly purified B cells from those B cell-T cell cocultures was readily detectable at 24 h. To analyze the in vivo role of CTLA-4 on B cells, we generated bone marrow chimeric mice, in which the CTLA-4 deficiency was restricted to B cells. We discovered that development and homeostasis of B cells was independent of CTLA-4, as well as the production of natural Abs. Intriguingly, the Ag-specific IgM and temporal IgE Ab production after a TD immunization was down-regulated on CTLA-4-expressing B cells, even after a second antigenic challenge in vivo. These data are the first demonstrating a role for CTLA-4 on B cells in vivo.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Mice

Mice transgenic (tg) for the DO.11.10 {alpha}β TCR (OVA-specific TCR) on a BALB/c background (a gift from D. Y. Loh, Washington University School of Medicine, St. Louis, MO), BALB/c, C57BL/6, CTLA-4–/– (a gift from J. P. Allison, University of California at Berkeley) and µMT (from Charles River Laboratories), the latter both on a C57BL/6 background, were bred and/or kept in the animal facility of the Bundesinstitut für Risikobewertung in Berlin. Mice were kept under specific pathogen-free conditions and used between 6 and 12 wk, or 3 and 4 wk for the CTLA-4–/–, of age. CTLA-4–/– mice were bred heterozygously, and offspring were genotyped by PCR at the age of 2–3 wk as described earlier (11).

Abs and reagents

The following Abs against murine Ags were used: anti-CD19 (1D3; BD Biosciences), anti-CD40 Ab (3/23; BD Pharmingen), anti-trinitrophenol (A 19-3; BD Biosciences), anti-CD86 (GL1; BD Pharmingen), anti-Ha-IgG (Jackson ImmunoResearch Laboratories), anti-CD69 (H1.2F3; BD Pharmingen), anti-{kappa} (187.1), anti-CD3 (145-2C11), anti-CD4 (GK-1.5/4), anti-B220 (RA3.6B2), anti-MHC II (M5/114) and anti-CTLA-4 (UC10-4F10), anti-IgM (AF3), and anti-IgD (11.26C) were purified from hybridoma supernatants with protein G columns. Abs were used unconjugated for cell culture or in conjugates of FITC, PE, and Cy5. Abs for ELISA were: coating Ab anti-mouse Ig (H + L) and detection Ab goat anti-mouse IgG, IgG2a, IgG1, IgM, and IgE all coupled to alkaline phosphatase and para-nitrophenyl phosphate substrate were purchased from Southern Biotechnology Associates.

Magnetic microbeads anti-CD19, anti-CD43, anti-CD4, anti-CD90, anti-CD62 ligand, and anti-FITC multisort were purchased from Miltenyi Biotec. CpG and oligonucleotide primer were obtained from TibMolBiol LPS from Escherichia coli and Con A were purchased from Sigma-Aldrich. IL-4 was purified from supernatants of P3X63 myeloid cells as well as GM-CSF was purified from culture supernatants. Sulfate polystyrene latex microspheres of 5 ± 0.1-µm mean diameters were obtained from Interfacial Dynamics.

In vitro culture systems

B cells were isolated using MACS either by depletion of none B cells with anti-CD43 microbeads or via positive selection with anti-CD19 microbeads according to the manufacturers’ instructions. Isolated B cell were stimulated with CpG (1 µM), LPS (40 µg/ml), anti-CD19 (10 µg/ml), anti-CD40 (1 µg/ml), anti-{kappa} (10 µg/ml), IL-4 (5 ng/ml), or anti-CD40 microspheres for the indicated time points. Latex microspheres were coated as described previously (11, 34) and B cells were stimulated at a ratio of 1:1 with Ab-coupled microspheres.

Three different B cell/T cell coculture systems were applied. At first B cells preincubated with LPS (40 µg/ml) or left untreated were stimulated with naive TCRtg/tg CD4+ T cells (isolated with anti-FITC multisort and CD62 ligand microbeads) in a ratio of 3:1 and 1 µg/ml OVA323–339 (Schneider/Mergener) for the indicated periods. Second, B cell containing APCs were obtained by depletion of T cells with anti-CD90 microbeads and stimulated with TCRtg/tg Th2 effector cells in a ratio of 3:1 and 1 µg/ml OVA323–339 for the indicated periods. Th2 effector cells were generated as described elsewhere (11). Third, for the coculture of T cell-depleted B cell-containing splenocytes from CTLA-4+/+ or CTLA-4–/– mice with T cells from CTLA-4+/+ mice, splenocytes were obtained by depletion of CD90+ cells with anti-CD90 microbeads and T cells were sorted with anti-CD4 microbeads by MACS. The respective T cell-depleted B cell-containing splenocytes were incubated with T cells from CTLA-4+/+ mice in a ratio of 3:1 and stimulated with 5 µg/ml Con A and 30 ng/ml IL-4 for 48 h. Total splenocytes were cultured with Con A (3 µg/ml) or CpG (1 µM). All the different types of cells were cultured in RPMI 1640 (PAA Laboratories) supplemented with 10% FCS (Sigma-Aldrich), 100 U/ml penicillin, 0.1 mg/ml streptomycin (both PAA Laboratories), and 10 µM 2-ME and were kept in a humidified incubator at 5% CO2.

Generation of bone marrow-derived dendritic cells (DCs)

Bone marrow cells of BALB/c mice were differentiated to DCs with GM-CSF and taken on day 6 for experiment.

FACS analysis

Surface and intracellular expression of CTLA-4 was detected using immunofluorescent liposomes as described elsewhere (35). Cytometric analyses were performed using a FACSCalibur (BD Biosciences) and CellQuest software (BD Biosciences). Dead cells were excluded by forward/side scatter gating and propidium iodide staining in life cell analysis.

mRNA analysis from purified B cells

B cells were purified from T cell cocultures 24 h after stimulation by depletion of T cells with anti-CD90 microbeads and were subsequently further purified by FACSort (Diva; BD Biosciences) to a purity of 99.9%. Total RNA from frozen cell pellets was extracted by using a RNeasy Mini Kit (Qiagen) and reversely transcribed into cDNA (Invitrogen Life Technologies). RT-PCR was performed using the following oligonucleotide primer: for CTLA-4, 5'-ACTCTGCTCCCTGAGGACCTCAG-3' and 5'-GGATGGTGAGGTTC-ACTCTGC-3'; for linker for activation of T cells (LAT), 5'-TCAGATGATGCCAACAGTGTGG-3' and 5'-TTCCT-CTTCTCCTTCGTCTTCC-3'; and for β-actin, 5'-TGGAATCCTGTGGCATCCATGAAAC-3' and 5'-TAAAACGCAGCAGTAACAGTCCG-3'.

Generation of chimeric mice and analysis of lymphocyte reconstitution

The bone marrow chimeras were generated as described elsewhere (36). In brief, recipient C57BL/6 mice were lethally irradiated with 10.5 Gy. Twenty-four hours thereafter, recipient mice were reconstituted with T cell-depleted bone marrow cells with a total of 3 x 106 cells i.v. By combination of bone marrow cells from different donors, three different groups of mice were generated: group 1, C57BL/6 B cells (80% µMT plus 20% C57BL/6); group 2, CTLA-4–/– B cells (80% µMT plus 20% CTLA-4–/–); and group 3, 80% C57BL/6 plus 20% CTLA-4–/– (80% C57BL/6 plus 20% CTLA-4–/–). Reconstitution of the recipient mice was checked 7.5–8 wk after cell transplantation. For that, blood from mice tail veins was examined by flow cytometry.

Immunization and detection of natural and Ag-specific Abs by ELISA

Eight weeks after cell transplantation, the chimeric mice were immunized with 150 µg of DNP-keyhole limpet hemocyanin (KLH) in alum in 200 µl i.p. A secondary immunization with 150 µg of DNP-KLH was given 7 wk after primary immunization. For analysis of natural or Ag-specific Abs, blood was taken from the tail veins of mice after the indicated time points and serum was obtained by a double centrifugation step. Plates for analysis of natural Abs were coated with 1 µg/ml anti-mouse Ig (H + L) and for Ag-specific Ab analysis plates were coated with 50 µg/ml DNP-BSA overnight. After extensive washing, the serum was incubated with an 8-point serial dilution in PBS for 2 h at room temperature. After washing the plates, the respective Ab subtype was detected by goat anti-mouse IgG (or IgG1, IgG2a, IgM, and IgE) coupled to alkaline phosphatase. As a substrate, para-nitrophenyl phosphate was taken and the plates were read at 405 nm after individual incubation times. The relative titer was determined by using a positive serum as a standard on each plate. Specificity was controlled by a negative serum pooled from C57BL/6 mice or by taking preimmune serum.

Statistics

Statistical evaluation was performed using Prism version 3.0cx software. The Mann-Whitney U test was used for analyzing differences in DNP-specific Ab production of chimeric mice.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
T cell-dependent intracellular CTLA-4 protein expression in B cells in vitro

A limited number of publications suggest the expression of CTLA-4 by B cells and there is controversial discussion whether this expression is regulated by other immune cells, especially T cells. Therefore, we investigated T cell-dependent and -independent culture systems in vitro to clarify the conditions for CTLA-4 expression on B cells. To investigate T cell-independent B cell cultures for CTLA-4-expressing cells, we purified B cells from mouse splenocytes and cultured these cells with LPS, anti-{kappa} (BCR cross-linking), anti-CD19, and anti-CD40 Abs, or anti-CD40 latex microspheres with or without further addition of IL-4. We were not able to detect any intracellular CTLA-4 expression in B cells (identified by CD19, B220, or CD86) under these culture conditions, although the B cells were activated, proliferated, and secreted Abs (Fig. 1A and data not shown). The intracellular CTLA-4 staining was controlled by intracellular CTLA-4 staining of CD4 cells activated with Con A in a splenocyte culture (Fig. 1A, top panel). There was also no intracellular CTLA-4 expression in the described B cell cultures at different time points (12, 24, 48, 96, or 120h) after stimulation (Fig. 1A and data not shown).


Figure 1
View larger version (38K):
[in this window]
[in a new window]

  		FIGURE 1. B cells express CTLA-4 protein. A, Isolated B cells do not express CTLA-4 when stimulated with LPS, CpG, anti-{kappa}, anti-CD19, and anti-CD40 Abs or anti-CD40 Latex microspheres and IL-4. Splenocytes of BALB/c mice were stimulated for 48 h with 3 µg/ml Con A. B cells were isolated from BALB/c mice through depleting CD43+ cells with anti-CD43 microbeads by MACS and stimulated for 48 h with the indicated conditions of LPS (40 µg/ml), CpG (1 µM), anti-{kappa} (10 µg/ml), anti-CD19 (10 µg/ml), anti-CD40 (1 µg/ml), anti-CD40 microspheres (microsphere:cell ratio 1:1), and IL-4 (5 ng/ml). After fixation, intracellular CTLA-4 was assayed by flow cytometry in CD4+ or in B cells (identified by CD19, B220, or CD86) from the isolated B cell cultures. The specificity of the staining was controlled by using an isotype-matched Ab (control). The numbers within the gates are percent CTLA-4+ cells calculated from total CD4+, B220+, CD19+, or CD86+ cells. Representative dot plots from two to three similar independent experiments are shown. B, B cells express intracellular CTLA-4 in T cell- dependent culture systems. Total splenocytes of BALB/c mice were stimulated for 48 h with 3 µg/ml Con A or 1 µM CpG (top and middle panels). Additionally, TCRtg/tg Th2 effector cells were stimulated with T cell-depleted B cell- containing splenocytes in a ratio of 1:3 with 1 µg/ml OVA323–339 for 48 h (lower panel). After fixation, intracellular CTLA-4 was assayed by flow cytometry on CD19+ B cells. The specificity of the staining was controlled by using an isotype-matched Ab (control). The numbers within the gates are percent CTLA-4+CD19+ cells. Representative dot plots from four independent experiments are shown. C, Intracellular CTLA-4 expression in B cells is maximal between 48 and 72 h after stimulation. Splenocytes of BALB/c mice were stimulated for the indicated time periods with 3 µg/ml Con A. After fixation, intracellular CTLA-4 was assayed by flow cytometry on CD4+ T cells ({square}) and CD19+ ({blacksquare}) B cells. CD19+ ({blacktriangledown}) cells from unstimulated cultures were taken as control. Data from three independent experiments are combined and expressed as percent CD4+CTLA-4+ or CD19+CTLA-4+ cells ± SEM.

 
CpG oligonucleotides bind TLR9 on B cells and trigger them to differentiation and proliferation (37). No CTLA-4 expression in B cells was found on enriched B cells stimulated with CpG alone (Fig. 1A). But taking total splenocytes and stimulating them with CpG, T cells are probably activated in this setting, which has been shown in a system with autoreactive T cells through IL-12 produced by the APCs in response to CpG (38). When we stimulated total splenocytes (containing T and B cells) with CpG or Con A, up to 12% of all CD19+ B cells did show intracellular CTLA-4 expression 48 h after stimulation (Fig. 1B, upper and middle panels). When we used Th2 effector cells, polarized for 1 wk, and stimulated them with T cell-depleted B cell- containing splenocytes and the corresponding Ag for 48 h, we could detect intracellular CTLA-4 expression in up to 19% of all of the CD19+ B cells (Fig. 1B, lower panel). The kinetics of intracellular CTLA-4 expression in B cells revealed no CTLA-4 on B cells at 24 h after stimulation (Fig. 1C). The peak expression of CTLA-4 on B cells was observed between 48 and 72 h with 11.3 ± 3.7% and 14.1 ± 5.2% CTLA-4+CD19+ B cells, respectively (Fig. 1C). The expression of CTLA-4 on B cells decreased after 96 h to 7.1 ± 3.4% positive B cells (Fig. 1C). The kinetics of intracellular CTLA-4 expression in B cells is similar to the kinetics of intracellular CTLA-4 expression on T cells in the same cultures, but the overall expression of CTLA-4 on T cells is approximately four times higher with up to 80% (Fig. 1C). In T cells, there is still a substantial proportion of cells positive for intracellular CTLA-4 after 5 days, in contrast to B cells where the CTLA-4 is almost undetectable after 5 days of culture (data not shown). To summarize these results, we were able to detect intracellular CTLA-4 in B cells when stimulating them in the presence of activated T cells. The intracellular CTLA-4 expression is restricted to a proportion of ~20% of all B cells in the culture and the expression is transient with a peak expression of 48–72 h after stimulation.

B cells express mRNA and protein of CTLA-4

Since we were able to detect CTLA-4 protein in B cells only in the presence of T cells, the question arose whether this CTLA-4 protein was taken up from CTLA-4- expressing T cells or whether the protein originates from the transcription of the CTLA-4 gene in the B cell itself. The possibility of molecule exchange between immune cells in close contact has been described previously (39, 40). Importantly when B and T cells are in close contact, only unidirectional molecule transfer from B cells to T cells has been found (41, 42). However, to exclude transfer of CTLA-4 molecules from T cells to B cells formally, we isolated B cell-containing APCs from either CTLA-4–/– or CTLA-4+/+ mice and stimulated them with CD4+ T cells from CTLA-4+/+ mice and Con A for 48 h. After the stimulation time, we found no difference in the up-regulation of CD69 expression of B cells from CTLA-4–/– and CTLA-4+/+ mice (Fig. 2A), demonstrating that the activation of B cells from either genotype was similar in these cultures. When analyzing the expression of CTLA-4, there was no CTLA-4 expression detectable in B cells in the cultures with B cells from CTLA-4–/– mice as compared with 16% CTLA-4-positive B cells in the culture with CTLA-4+/+ B cells (Fig. 2B). Since CTLA-4 was detectable on T cells of both cultures, no transfer of molecules from T cells to B cells has occurred (Fig. 2B). Similar results were obtained stimulating CTLA-4+/+ T cells with Con A in cocultures of CFSE-labeled CTLA-4–/– B cells along with CTLA-4+/+ B cells (data not shown).


Figure 2
View larger version (35K):
[in this window]
[in a new window]

  		FIGURE 2. CTLA-4 protein in B cells is not a result of molecule transfer from T cells and CTLA-4 mRNA is transcribed in primary B cells. A and B, CTLA-4 protein in B cells is not a result of molecule transfer from activated T cells. T cell-depleted B cell-containing splenocytes were obtained from CTLA-4+/+ C57BL/6 or CTLA-4–/– C57BL/6 mice by depletion of CD90+ cells with anti-CD90 beads by MACS. T cells were derived from CTLA-4+/+ C57BL/6 mice via positive selection of CD4+ splenocytes with anti-CD4 microbeads by MACS. The respective T cell-depleted B cell-containing splenocytes were incubated with T cells from CTLA-4+/+ mice in a ratio of 3:1 and stimulated with 5 µg/ml Con A and 30 ng/ml IL-4 for 48 h. A, B cells from CTLA-4+/+ or CTLA-4–/– mice are activated in T cell cocultures. The histogram shows the overlay of CD69 cells from CTLA-4+/+ (gray shaded area) or CTLA-4–/– (thick black line) mice gated on CD19+ cells. The thin black line represents the isotype control for CD69 staining. Representative data from two independent experiments are shown. B, B cells do not take up CTLA-4 from activated CTLA-4+ T cells. After fixation, intracellular CTLA-4 was assayed by flow cytometry on CD19+ B cells. The dot plots show the intracellular CTLA-4 and the numbers indicate CD19+CTLA-4+ cells in cultures with CTLA-4–/– B cells and with CTLA-4+/+ B cells. The specificity of the staining was controlled by using an isotype-matched Ab. Representative data from two similar independent experiments are shown. C and D, TCRtg/tg Th2 effector cells were stimulated with T cell- depleted B cell-containing splenocytes in a ratio of 1:3 with 1 µg/ml OVA323–339 for 24 h. CD19+ B cells were enriched using MACS and further purified by FACS technology to a purity of 99.9%. C, The dot plot represents the analysis of the enriched CD19+ B cells. D, CTLA-4 mRNA is detectable in B cells 24 h after stimulation. Total RNA from B cells, T cells, and bone marrow-derived DCs were extracted and reversely transcribed into cDNA. CTLA-4 mRNA was amplified by PCR. The purity of the B cell preparation is controlled by amplification of LAT, which is only detectable in T cells. Representative data from three independent experiments are shown.

 
To analyze the CTLA-4 mRNA in B cells, we performed RT-PCRs from highly enriched B cells after stimulating them in a T cell-dependent culture system. We stimulated the B cells along with Th2 effector cells and cognate Ag (Fig. 1B) and enriched B cells from this culture 24 h after stimulation to a purity of 99.9% (Fig. 2C). The cDNA of these highly enriched B cells, of activated T cells as well as of DCs, were analyzed for CTLA-4 expression using PCR. CTLA-4 mRNA was detectable in the T cells, but also in the B cells (Fig. 2D). CTLA-4 mRNA was not detectable in DCs. To exclude any contaminating CTLA-4+ T cells in the highly enriched B cells, we analyzed the mRNA for LAT, which is only expressed in T cells, but not in splenic B cells (43, 44). We could not detect mRNA for LAT in the B cell preparation, excluding the contribution of contaminating T cells (Fig. 2D). It might be of note that CTLA-4 mRNA is not detectable in B cells ex vivo (data not shown).

Surface CTLA-4 expression on activated B cells in T cell-dependent culture systems

To interact with its ligands B7-1 and B7-2, CTLA-4 has to be expressed on the surface of B cells. Since the CTLA-4 molecule is expressed only in very low numbers on the surface of T cells, we used an established staining-enhancing method based on fluorescent liposomes (11, 12, 33) to detect surface CTLA-4-positive B cells. We used total splenocytes (containing T and B cells) stimulated with Con A or Th2 effector cells stimulated with the cognate Ag and B cell- containing APCs. We were able to detect between 11 and 15% surface CTLA-4+CD19+ B cells with the liposome technique (Fig. 3A). Because the culture systems used so far contained also other cells, e.g., DCs and macrophages, although in very low numbers, we next analyzed CTLA-4 expression on B cells in exclusive B and T cell cocultures. We stimulated enriched (98%) B cells, either preincubated with LPS or ex vivo, along with purified T cells and the cognate Ag and analyzed CTLA-4 expression on B cells. We detected 9.7 ± 2.5% surface CTLA-4+CD19+ B cells when using preactivated B cells (Fig. 3B). Preactivation of B cells with LPS did not influence the surface CTLA-4 expression of B cells, since we observed 9.05 ± 2.1% surface CTLA-4+CD19+ B cells without preactivation of the B cells before the coculture with T cells (Fig. 3B). However, phenotypical analysis of the activation status of surface CTLA-4+ as compared with surface CTLA-4– B cells, 48 h after stimulation with Th2 effector cells and cognate Ag, revealed no difference with regard to expression of surface receptors that are induced (CD69) or altered in their expression (MHC II, CD40, and CD86) after activation (Fig. 3C). Both populations showed a clear induction of CD69 and up-regulation of CD86 on B cells after 48 h of culture, whereas CD40 remained unchanged and MHC II expression was down-regulated (Fig. 3C). Likewise, surface CTLA-4- expressing T cells show similar activation marker expression to CTLA-4– T cells. Taken together, surface CTLA-4+ B cells are clearly detectable in T cell-dependent culture systems using the staining-enhancing liposome technique and they up-regulate expression of activation-induced genes after activation.


Figure 3
View larger version (28K):
[in this window]
[in a new window]

  		FIGURE 3. B cells express surface CTLA-4 in T cell-dependent culture systems in vitro. A, B cells express surface CTLA-4 in T cell-dependent culture systems. Total splenocytes of BALB/c mice were stimulated for 48 h with 3 µg/ml Con A (upper panel) or TCRtg/tg Th2 effector cells were stimulated with T cell-depleted B cell-containing splenocytes in a ratio of 1:3 with 1 µg/ml OVA323–339 for 48 h (lower panel). Surface CTLA-4+ B cells were identified by using enhanced staining with liposomes and cytometric detection. Specific staining was controlled by blocking with an unconjugated anti-CTLA-4 Ab before the use of anti-CTLA-4-digoxigenin Ab. The numbers within the gates are percent CTLA-4+CD19+ cells. Representative dot plots from three independent experiments are shown. B, Surface CTLA-4 expression on B cells is irrespective of the presence of other APCs and irrespective of B cell preactivation with LPS. B cells were isolated from splenocytes of BALB/c mice with positive sort of CD19+ cells with anti-CD19 microbeads by MACS. B cells were either preactivated for 24 h with 40 µg/ml LPS or B cells were directly (ex vivo) stimulated with naive TCRtg/tg CD4+ T cells in a ratio of 3:1 and 1 µg/ml OVA323–339 for the indicated periods. Surface CTLA-4+ B cells from cultures with LPS-preactivated B cells (Figure 3) and from cultures with B cells ex vivo ({blacksquare}) were identified by using enhanced staining by liposomes and cytometric detection. Specific staining was controlled by using an isotype-matched control Ab. Data from three to four independent experiments are combined and expressed as percent CTLA-4+CD19+ cells ± SEM. C, Surface CTLA-4-positive B cells express CD69, MHC, CD40, and CD86. TCRtg/tg Th2 effector cells were stimulated with T cell-depleted B cell- containing splenocytes in a ratio of 1:3 with 1 µg/ml OVA323–339 for 48 h. Forty-eight hours after stimulation, B cells were enriched by depletion of CD90+ cells with anti-CD90 microbeads by MACS. Surface CTLA-4+ B cells were identified by using enhanced staining by liposomes and cytometric detection. Specific staining was controlled by using an unconjugated anti-CTLA-4 Ab before the use of anti-CTLA-4-digoxigenin Ab. The expression of CD69, MHC, CD40, and CD86 on the surface of CTLA-4+CD19+ cells (gray shaded curve) as compared with the expression on CTLA-4–CD19+ cells (thick black line) was analyzed. The thin black line within the histograms represents expression of CD69, MHC, CD40, and CD86 on total CD19+ cells ex vivo, respectively. Representative data from three independent experiments are shown.

 
Normal B and T cell homeostasis and development in mice with a CTLA-4 deficiency of B cells

So far there is no established role for CTLA-4- expressing B cells in vivo. There are suggestive data claiming that CTLA-4 might influence isotype class switching to IgG1 and IgE in vitro (25, 45). B cells from the CTLA-4–/– mice display an activated phenotype and all Ab classes show elevated titers compared with CTLA-4+/+ animals (31, 32). The B cell phenotype in CTLA-4–/– mice could either be B cell intrinsic or a secondary resort of CTLA-4- deficient activated T cells. To analyze the role for CTLA-4 on B cells in vivo, we generated bone marrow chimeric mice, in which CTLA-4 deficiency is restricted to the B cells and the majority of the T cells are CTLA-4 competent (36). Eight weeks after reconstitution of the irradiated animals, the peripheral B cell as well as T cell pool of the chimeric mice was analyzed by FACS. There was no significant difference in the frequencies of peripheral B cells in CTLA-4–/– B cell chimeric mice as compared with C57BL/6 B cell chimeric mice, respectively (Fig. 4A). In addition, we discriminated the pool of total B cells into developmental B cell stage T1 (CD19+IgMhighIgDlow) and the mature B cell stage (CD19+IgMintIgDhigh) in accordance with the study of Carsetti et al. (46). As for the total frequency of CD19+ cells, there was no difference in the CTLA-4–/– B cell chimeric mice as compared with C57BL/6 B cell chimeric mice (Fig. 4A). The peripheral T cell pool, divided into CD4+ and CD8+ cells, is as well reconstituted in the CTLA-4–/– B cell chimeric mice (Fig. 4B). Furthermore, we analyzed the natural Ab production, mainly produced by B1 B cells, in the CTLA-4–/– B cell chimeric mice. No difference in the Ab titer of natural IgM and total IgG Abs could be observed between the CTLA-4–/– B cell chimeric mice and the C57BL/6 B cell chimeric mice (Fig. 5A). Thus, B and T cell development and homeostasis are normal in mice with a CTLA-4 deficiency of B cells.


Figure 4
View larger version (18K):
[in this window]
[in a new window]

  		FIGURE 4. Lymphocyte reconstitution of CTLA-4–/– B cell chimeric mice is normal. C57BL/6 mice were lethally irradiated and reconstituted with 80% bone marrow from µMT mice plus 20% bone marrow from C57BL/6 mice (C57BL/6 B cells, {square}) or reconstituted with 80% bone marrow from µMT mice plus 20% bone marrow from CTLA-4–/– (C57BL/6 background) mice (CTLA-4–/– B cells, {blacksquare}). The blood of these chimeric mice was analyzed for different lymphocyte populations by flow cytometry 8 wk after reconstitution. The bar graphs represent combined data from seven animals. A, The frequencies of total CD19+ cells, immature T1 B cells (CD19+IgMhighIgDlow), and mature B cells (CD19+IgMinterm.IgDhigh) ± SD are depicted. B, The frequencies of total CD4+ and CD8+ cells ± SD are depicted. Representative data from three independent experiments are shown.

 

Figure 5
View larger version (38K):
[in this window]
[in a new window]

  		FIGURE 5. Elevated DNP-specific IgM and temporal IgE response in CTLA-4–/– B cell chimeric mice after primary and secondary TD immune response. C57BL/6 mice were lethally irradiated and reconstituted with 80% bone marrow from µMT mice plus 20% bone marrow from C57BL/6 mice (C57BL/6 B cells ({square})) or reconstituted with 80% bone marrow from µMT mice plus 20% bone marrow from CTLA-4–/– (C57BL/6 background) mice (CTLA-4–/– B cells ({blacksquare})). Each square in the diagrams represents data from a single mouse. The relative titer was calculated as described in Materials and Methods. A, Natural IgM and IgG titers are unaltered in CTLA-4–/– B cell chimeric mice as compared with C57BL/6 B cell chimeric mice. The serum of these chimeric mice was analyzed for natural IgM and IgG titers by ELISA 8 wk after reconstitution. Representative data from three independent experiments are shown. B, Elevated DNP-specific IgM Ab titer in CTLA-4–/– B cell chimeric mice after primary and secondary immunization. The primary immunization was done with 150 µg of DNP-KLH in alum i.p. 8.5 wk after reconstitution. A secondary immunization with DNP-KLH (150 µg) was given 7 wk after primary immunization. The serum of the chimeric mice was analyzed for DNP-specific IgM, IgG1, IgG2a, and IgE Ab production by ELISA at the indicated time points. Data from two independent experiments were combined. C, The elevated DNP-specific IgM Abs are not controlled by the 20% CTLA-4–/– T cells. A third group of chimeric mice was generated by lethal irradiation of C57BL/6 mice and reconstitution with 80% bone marrow from C57BL/6 mice plus 20% bone marrow from CTLA-4–/– mice (80% C57BL/6 + 20% CTLA-4–/– ({blacksquare})). The serum of the chimeric mice was analyzed for natural IgM and IgG titers by ELISA 8 wk after reconstitution. Representative data from three independent experiments are shown. The chimeric mice were immunized as described in B and 2 wk after secondary immunization DNP-specific IgM Abs were analyzed by ELISA. Data from two independent experiments were combined.

 
Elevated DNP-specific IgM and temporal IgE response in CTLA-4–/– B cell chimeric mice after primary and secondary TD immune responses

Because we discovered a T cell-dependent CTLA-4 induction on B cells, we used a TD immunization protocol with 150 µg of DNP-KLH in alum to analyze the role for CTLA-4 on B cells for Ab production. We immunized the chimeric mice and determined DNP-specific Ab titers of IgM, IgG1, IgG2a, and IgE subclasses at 1 and 3 wk after primary immunization by ELISA. We found a significantly higher DNP-specific IgM Ab production at 1 and 3 wk postimmunization in the CTLA-4–/– B cell chimeric mice as compared with the C57BL/6 B cell chimeric mice (Fig. 5B). The DNP-specific Ab titers of the IgG1 and IgG2 subclasses did not show any difference between the groups of chimeric mice (Fig. 5B). Concerning the DNP-specific IgE Ab response, we found a significantly higher Ab titer 3 wk postimmunization in the CTLA-4–/– B cell chimeric mice as compared with the C57BL/6 B cell chimeric mice (Fig. 5B). To study the B cell memory response, we immunized the chimeric mice 7.5 wk after primary immunization for a second time using 150 µg of DNP-KLH. We analyzed again the DNP-specific Ab titers 2 wk after the boost of the above-mentioned subclasses. Like for the primary response, we did find a significantly elevated DNP-specific IgM response in mice deficient for CTLA-4 in the B cell compartment, whereas all other Ab classes remained unchanged (Fig. 5B).

The observed elevated Ag-specific IgM and IgE Ab response cannot be attributed to the fraction of 20% CTLA-4-deficient T cells that are present in the B cell CTLA-4- deficient chimeric mice. This possibility was excluded by a third chimeric group of mice, with 20% of the T cells being CTLA-4 deficient and the majority of the B cells being CTLA-4 competent (Fig. 5C). DNP-specific IgM Ab titers after immunization of these mice did not show the elevated IgM response as observed in the CTLA-4–/– B cell chimeric mice, but rather a significantly lower DNP-specific IgM response (Fig. 5C). Thus, CTLA-4 on B cells can indeed negatively regulate the Ag-specific IgM and IgE response in TD immune responses.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
The importance of the CTLA-4 molecule for T cell differentiation and effector functions is well established. In contrast, the expression and potential relevance of expression of endogenous CTLA-4 for the differentiation of B cells has not been documented. In this study, we describe a T cell-dependent, activation-induced, and transient expression of CTLA-4 on murine B cells. Expression of CTLA-4 on the cell surface of B cells was detected by liposome-enhanced immunofluorescence and flow cytometry. The in vivo importance for CTLA-4- expressing B cells could be shown by the generation of chimeric mice, in which the CTLA-4 deficiency was restricted to the B cell compartment. Immunization of these chimeric mice with a TD protocol revealed that CTLA-4 on B cells controls the Ag-specific IgM responses of primary and secondary immune reactions in vivo.

We could show that isolated B cells stimulated with anti-CD40, anti-{kappa} L chain plus anti-CD40, anti-{kappa} L chain plus anti-CD19, LPS, and CpG with or without IL-4 do not up-regulate CTLA-4 in B cells. On the contrary (25, 45) and in line with earlier data for human B cells (26), we detected CTLA-4 on B cells cultured with activated T cells. Intracellular CTLA-4 in B cells is only detectable after stimulation, with a peak expression of 15–20% of all B cells at 48–72 h (Fig 1C). Surface CTLA-4+CD19+ cells were only detectable using the staining-enhancing liposome technique (11, 12, 33), thus showing that the frequency of surface CTLA-4-expressing B cells was hardly different than intracellular CTLA-4 expression in B cells (Fig. 3A), with up to 15% CTLA-4+CD19+ B cells. Equal expression of surface and intracellular CTLA-4 protein expression was suggested for B cells taken from the blood of patients with B cell chronic lymphocytic leukemia (27). This expression profile differs strikingly from CTLA-4 expression in T cells where one finds nearly all cells CTLA-4+ intracellularly, whereas only up to 12% of the T cells are also surface CTLA-4 positive, at least in a primary peptide stimulation (12). This shows that the way of intracellular storage of CTLA-4 in vesicles described for T cells is different for B cells, even tighter restricted, probably controlled by T cells, because B cells only express CTLA-4 when T cells do so. Because we excluded uptake of CTLA-4 protein from T cells, which is in line with data showing that T cells mainly take up B7 molecules and MHC from APCs and that this molecule transfer from APCs to T cells is usually unidirectional (39, 47), we assume that other molecules of T-B interactions are the trigger for CTLA-4 expression of B cells; the receptor ligand pathway CTLA-4/B7 could possibly perform this function. Alternatively, a certain subpopulation of B cells, such as B1, B2, or a subclass of B2, the marginal zone B cells, could differentially express CTLA-4. Since CTLA-4 on splenic B cells is only expressed when activated T cells are present, it is most likely that CTLA-4-expressing B cells belong to the follicular B cells, since these cells, in contrast to marginal zone and B1 B cells, interact with T cells in TD immune responses (48, 49). Still, one has to keep in mind that marginal zone B cells are able to interact with naive T cells, inducing a strong proliferation and cytokine production in them (50). No less interesting is the finding that follicular B cells have the potential to convert into marginal zone B cells (48). Further studies are needed to clarify the affiliation of the CTLA-4-expressing B cells to one or the other B cell subset.

To signal, CTLA-4 expressed on B cells requires cell-cell contact to cell types that express its ligand B7-1 or B7-2, such as DCs, macrophages, T cells, or even B cells themselves. There are a number of reports showing the expression and function of B7-1 and B7-2 molecules on T cells, which not only challenges the cell type-specific costimulator expression but also gives the opportunity of interaction of CTLA-4 on B cells with its ligand B7 on T cells (15, 16, 19, 51, 52). The CTLA-4/B7 pathways are even more complex, since engagement of B7 molecules on T cells is able to manipulate T cell functions; e.g., B7-1-deficient T cells show a significantly higher IL-4 production than wild-type T cells and B7-1/2–/– T cells are not controlled by regulatory T cells anymore depending on the cytoplasmic domain of the B7 molecule (19, 52). This possible criss-cross regulation of CTLA-4 and its ligand between T-T, T-B, and B-B lymphocytes shows that the traditional view is too simple. CTLA-4 on B cells might well interact with B7 molecules on other B cells, according to our data probably in the B cell zone, where B cells are migrating to, after activation with T cells in the T cell zone.

We show here that CTLA-4 on B cells inhibits B cell effector functions. Since recently, the traditional view of CTLA-4 inhibitory effects on T cell responses was merely attributed to its inhibitory effect of inducing cell cycle arrest (12, 34, 53). New data now demonstrate that CTLA-4 signaling can indeed down-regulate effector molecules such as IFN-{gamma} of individual CD8 T cells (35). One or both functions of CTLA-4 mentioned could explain the enhanced Ab production caused by the genetic inactivation of CTLA-4 on B cells (12, 34, 54, 55). Alternatively, different actions of receptors depending on the cell type specific expression are shown, which might also hold true for CTLA-4 on B cells. This is exemplified by B7-2 molecules on T cells, (16) or CD28 on plasma cells (22, 56). As our research has demonstrated that already intracellular trafficking of CTLA-4 to the cell surface differs between T and B cells, we favor the notion that initiated signaling pathways of CTLA-4 might differ also between T and B cells.

Perhaps most importantly, we have been able to identify a new role for CTLA-4 on B cells in vivo in TD immune responses. Altered development or homeostasis of B cells in B cell CTLA-4–/– chimeric mice was ruled out, hence the effects in Ab production are not due to different cell numbers of Ag unexperienced B cells. Furthermore, analysis of natural IgM and total IgG titers in the chimeric mice before immunization revealed no difference in the CTLA-4–/– chimeric mice as compared with CTLA-4+/+, stressing the point that only T cell-dependent actions of B cells lead to CTLA-4 expression in B cells (natural Abs are T cell independent) (48). In a TD immune reaction, T cell and B cells meet in the T cell zone, where CTLA-4 on B cells could be induced. As early as 7 days after immunization with DNP-KLH, we observed a significantly higher Ag-specific IgM production in sera of CTLA-4–/– B cell chimeric mice as compared with wild type. These Abs are probably generated by Ab-forming cells of the primary focus, since Abs from the germinal centre are only detectable from about day 10 on after immunization (49). CTLA-4 on B cells might regulate the number of B cells in the primary focus by either dampening the proliferation at place, or by influencing the mobility of the B cells migrating from the primary focus to the B cell primary follicle. Further studies are needed to analyze the number of B cells in the early germinal center, determined by peanut agglutinin high cells (57), to clarify a role for CTLA-4 in B cell migration. The early Abs produced in a TD immune response are not only for immediate protection of the host, but also give rise to Ag-Ab complexes on follicular DCs and may regulate the long-term Ab response. Three weeks after immunization, we still found significant elevated levels of Ag-specific IgM Abs in the CTLA-4–/– B cell chimeric mice. Since T cells are able to express CTLA-4 at all differentiation steps (10, 11, 12), we assume that CTLA-4 on B cells is able to down-modulate "late IgM" Abs originating from unswitched Ab-forming cells of the germinal center reaction (58), but at the same time also regulate IgM Abs produced by terminal differentiated long-lived plasma cells of the primary focus (59, 60).

Apart from the elevated Ag-specific IgM titers, we also found elevated Ag-specific IgE titers at least 3 wk after primary immunization in the CTLA-4–/– B cell chimeric mice. This implies another regulatory checkpoint for CTLA-4 on B cells in the germinal center reaction. Studies in vitro suggested a role for CTLA-4 on B cells activated by anti-CD40 plus IL-4 in the IgE production via inactivation of STAT6 and NF-{kappa}B, which we could not confirm (Fig. 1A and Ref. 25). Because reduced IgE production in vivo is not seen after boosting, we assume an indirect regulation (Fig. 5B). In a secondary Ab response, we again detected significant elevated Ag-specific IgM Abs. Whether these derive from naive B cells or from the recently identified IgM-positive memory B cell pool has to be determined in the future (61). A role for CTLA-4 for differentiation or maintenance of memory cells is intriguing, as a fraction of CTLA-4+ B cells could get survival signals, similar to a fraction of CTLA-4-expressing T cells (11), and could therefore take part in the memory formation.


   Acknowledgments
 
We thank Heike Hirseland for excellent technical assistance, Andreas Radbruch for his support, David Gray for his support during Dagmar Quandt’s Deutscher Akademischer Austauschdienst-supported exchange visit, and Alexander Scheffold and Jim Allison for providing us with fluorescence liposomes and CTLA-4-deficient mice, respectively.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by the Deutsche Forschungsgemeinschaft Br1860, Deutscher Akademischer Austauschdienst grant (to D.Q.), NAFöG Berlin grants (to D.Q. and H.H.), and "Persönliche Forschungsförderung" of the Charité-niversitätsmedizin Berlin (to M.C.B.W.). Back

2 Address correspondence and reprint requests to Dr. Monika C. Brunner-Weinzierl, Department of Paedriatrics, University Hospital Magdeburg, Leipziger Strasse 44, Magdeburg, 39104 Germany. E-mail address: Monika.Brunner-Weinzierl{at}med.ovgu.de Back

3 Abbreviations used in this paper: TD, thymus dependent; MHC II, MHC class II; tg, transgenic; DC, dendritic cell; LAT, linker for activation of T cells; KLH, keyhole limpet hemocyanin. Back

Received for publication July 5, 2007. Accepted for publication September 21, 2007.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Fagarasan, S., T. Honjo. 2000. T-independent immune response: new aspects of B cell biology. Science 290: 89-92. [Abstract/Free Full Text]
  2. Mills, D. M., J. C. Cambier. 2003. B lymphocyte activation during cognate interactions with CD4+ T lymphocytes: molecular dynamics and immunologic consequences. Semin. Immunol. 15: 325-329. [Medline]
  3. Okada, T., M. J. Miller, I. Parker, M. F. Krummel, M. Neighbors, S. B. Hartley, A. O’Garra, M. D. Cahalan, J. G. Cyster. 2005. Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells. PLoS Biol. 3: e150[Medline]
  4. Greenwald, R. J., G. J. Freeman, A. H. Sharpe. 2005. The B7 family revisited. Annu. Rev. Immunol. 23: 515-548. [Medline]
  5. Durie, F. H., T. M. Foy, S. R. Masters, J. D. Laman, R. J. Noelle. 1994. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol. Today 15: 406-411. [Medline]
  6. Shanebeck, K. D., C. R. Maliszewski, M. K. Kennedy, K. S. Picha, C. A. Smith, R. G. Goodwin, K. H. Grabstein. 1995. Regulation of murine B cell growth and differentiation by CD30 ligand. Eur. J. Immunol. 25: 2147-2153. [Medline]
  7. Crow, M. K.. 2004. Costimulatory molecules and T-cell-B-cell interactions. Rheum. Dis. Clin. N. Am. 30: 175-191. vii–viii. [Medline]
  8. Watts, T. H.. 2005. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23: 23-68. [Medline]
  9. Teft, W. A., M. G. Kirchhof, J. Madrenas. 2006. A molecular perspective of CTLA-4 function. Annu. Rev. Immunol. 24: 65-97. [Medline]
  10. Brunner-Weinzierl, M. C., H. Hoff, G. R. Burmester. 2004. Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases. Arthritis Res.Ther. 6: 45-54.
  11. Pandiyan, P., D. Gartner, O. Soezeri, A. Radbruch, K. Schulze-Osthoff, M. C. Brunner-Weinzierl. 2004. CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. J. Exp. Med. 199: 831-842. [Abstract/Free Full Text]
  12. Maszyna, F., H. Hoff, D. Kunkel, A. Radbruch, M. C. Brunner-Weinzierl. 2003. Diversity of clonal T cell proliferation is mediated by differential expression of CD152 (CTLA-4) on the cell surface of activated individual T lymphocytes. J. Immunol. 171: 3459-3466. [Abstract/Free Full Text]
  13. Chambers, C. A., M. S. Kuhns, J. G. Egen, J. P. Allison. 2001. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19: 565-594. [Medline]
  14. Egen, J. G., M. S. Kuhns, J. P. Allison. 2002. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3: 611-618. [Medline]
  15. Azuma, M., H. Yssel, J. H. Phillips, H. Spits, L. L. Lanier. 1993. Functional expression of B7/BB1 on activated T lymphocytes. J. Exp. Med. 177: 845-850. [Abstract/Free Full Text]
  16. Greenfield, E. A., E. Howard, T. Paradis, K. Nguyen, F. Benazzo, P. McLean, P. Hollsberg, G. Davis, D. A. Hafler, A. H. Sharpe, et al 1997. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. J. Immunol. 158: 2025-2034. [Abstract]
  17. Cross, A. H., J. A. Lyons, M. San, R. M. Keeling, G. Ku, M. K. Racke. 1999. T cells are the main cell type expressing B7-1 and B7-2 in the central nervous system during acute, relapsing and chronic experimental autoimmune encephalomyelitis. Eur. J. Immunol. 29: 3140-3147. [Medline]
  18. Taylor, P. A., C. J. Lees, S. Fournier, J. P. Allison, A. H. Sharpe, B. R. Blazar. 2004. B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]. J. Immunol. 172: 34-39. [Abstract/Free Full Text]
  19. Paust, S., L. Lu, N. McCarty, H. Cantor. 2004. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc. Natl. Acad. Sci. USA 101: 10398-10403. [Abstract/Free Full Text]
  20. Kozbor, D., A. Moretta, H. A. Messner, L. Moretta, C. M. Croce. 1987. Tp44 molecules involved in antigen-independent T cell activation are expressed on human plasma cells. J. Immunol. 138: 4128-4132. [Abstract]
  21. Widney, D., W. J. Boscardin, A. Kasravi, O. Martinez-Maza. 2003. Expression and function of CD28 on Epstein-Barr virus-positive B cell lines and AIDS-associated non-Hodgkin’s lymphoma cell lines. Tumour Biol. 24: 82-93. [Medline]
  22. Zhang, X. G., D. Olive, J. Devos, C. Rebouissou, M. Ghiotto-Ragueneau, M. Ferlin, B. Klein. 1998. Malignant plasma cell lines express a functional CD28 molecule. Leukemia 12: 610-618. [Medline]
  23. Xerri, L., E. Devilard, J. Hassoun, D. Olive, F. Birg. 1997. In vivo expression of the CTLA4 inhibitory receptor in malignant and reactive cells from human lymphomas. J. Pathol. 183: 182-187. [Medline]
  24. Raiter, A., A. Novogrodsky, B. Hardy. 1999. Activation of lymphocytes by BAT and anti CTLA-4: comparison of binding to T and B cells. Immunol. Lett. 69: 247-251. [Medline]
  25. Pioli, C., L. Gatta, V. Ubaldi, G. Doria. 2000. Inhibition of IgG1 and IgE production by stimulation of the B cell CTLA-4 receptor. J. Immunol. 165: 5530-5536. [Abstract/Free Full Text]
  26. Kuiper, H. M., M. Brouwer, P. S. Linsley, R. A. van Lier. 1995. Activated T cells can induce high levels of CTLA-4 expression on B cells. J. Immunol. 155: 1776-1783. [Abstract]
  27. Kosmaczewska, A., L. Ciszak, K. Suwalska, D. Wolowiec, I. Frydecka. 2005. CTLA-4 overexpression in CD19+/CD5+ cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients. Leukemia 19: 301-304. [Medline]
  28. Ravetch, J. V., L. L. Lanier. 2000. Immune inhibitory receptors. Science 290: 84-89. [Abstract/Free Full Text]
  29. Zeng, C., T. Wu, Y. Zhen, X. P. Xia, Y. Zhao. 2005. BTLA, a new inhibitory B7 family receptor with a TNFR family ligand. Cell. Mol. Immunol. 2: 427-432. [Medline]
  30. Leibson, P. J.. 2004. The regulation of lymphocyte activation by inhibitory receptors. Curr. Opin. Immunol. 16: 328-336. [Medline]
  31. Tivol, E. A., F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone, A. H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547. [Medline]
  32. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, H. Griesser, T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270: 985-988. [Abstract/Free Full Text]
  33. Gartner, D., H. Hoff, U. Gimsa, G. R. Burmester, M. C. Brunner-Weinzierl. 2006. CD25 regulatory T cells determine secondary but not primary remission in EAE: impact on long-term disease progression. J. Neuroimmunol. 172: 73-84. [Medline]
  34. Brunner, M. C., C. A. Chambers, F. K. Chan, J. Hanke, A. Winoto, J. P. Allison. 1999. CTLA-4-mediated inhibition of early events of T cell proliferation. J. Immunol. 162: 5813-5820. [Abstract/Free Full Text]
  35. Pandiyan, P., J. K. Hegel, M. Krueger, D. Quandt, M. C. Brunner-Weinzierl. 2007. High IFN-{gamma} production of individual CD8 T lymphocytes is controlled by CD152 (CTLA-4). J. Immunol. 178: 2132-2140. [Abstract/Free Full Text]
  36. Fillatreau, S., C. H. Sweenie, M. J. McGeachy, D. Gray, S. M. Anderton. 2002. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3: 944-950. [Medline]
  37. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549. [Medline]
  38. Conant, S. B., R. H. Swanborg. 2004. Autoreactive T cells persist in rats protected against experimental autoimmune encephalomyelitis and can be activated through stimulation of innate immunity. J. Immunol. 172: 5322-5328. [Abstract/Free Full Text]
  39. Sprent, J.. 2005. Swapping molecules during cell-cell interactions. Sci STKE 273: pe8
  40. Batista, F. D., D. Iber, M. S. Neuberger. 2001. B cells acquire antigen from target cells after synapse formation. Nature 411: 489-494. [Medline]
  41. Hwang, I., J. F. Huang, H. Kishimoto, A. Brunmark, P. A. Peterson, M. R. Jackson, C. D. Surh, Z. Cai, J. Sprent. 2000. T cells can use either T cell receptor or CD28 receptors to absorb and internalize cell surface molecules derived from antigen-presenting cells. J. Exp. Med. 191: 1137-1148. [Abstract/Free Full Text]
  42. Huang, J. F., Y. Yang, H. Sepulveda, W. Shi, I. Hwang, P. A. Peterson, M. R. Jackson, J. Sprent, Z. Cai. 1999. TCR-mediated internalization of peptide-MHC complexes acquired by T cells. Science 286: 952-954. [Abstract/Free Full Text]
  43. Horejsi, V., W. Zhang, B. Schraven. 2004. Transmembrane adaptor proteins: organizers of immunoreceptor signalling. Nat. Rev. Immunol. 4: 603-616. [Medline]
  44. Su, Y. W., H. Jumaa. 2003. LAT links the pre-BCR to calcium signaling. Immunity 19: 295-305. [Medline]
  45. Merlo, A., C. Tenca, F. Fais, L. Battini, E. Ciccone, C. E. Grossi, D. Saverino. 2005. Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes. Clin. Diagn. Lab. Immunol. 12: 705-712. [Medline]
  46. Carsetti, R., M. M. Rosado, H. Wardmann. 2004. Peripheral development of B cells in mouse and man. Immunol. Rev. 197: 179-191. [Medline]
  47. Sabzevari, H., J. Kantor, A. Jaigirdar, Y. Tagaya, M. Naramura, J. Hodge, J. Bernon, J. Schlom. 2001. Acquisition of CD80 (B7-1) by T cells. J. Immunol. 166: 2505-2513. [Abstract/Free Full Text]
  48. Matthias, P., A. G. Rolink. 2005. Transcriptional networks in developing and mature B cells. Nat. Rev. Immunol. 5: 497-508. [Medline]
  49. Shapiro-Shelef, M., K. Calame. 2005. Regulation of plasma-cell development. Nat. Rev. Immunol. 5: 230-242. [Medline]
  50. Attanavanich, K., J. F. Kearney. 2004. Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells. J. Immunol. 172: 803-811. [Abstract/Free Full Text]
  51. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180: 631-640. [Abstract/Free Full Text]
  52. Schweitzer, A. N., A. H. Sharpe. 1999. Mutual regulation between B7-1 (CD80) expressed on T cells and IL-4. J. Immunol. 163: 4819-4825. [Abstract/Free Full Text]
  53. Chambers, C. A., M. F. Krummel, B. Boitel, A. Hurwitz, T. J. Sullivan, S. Fournier, D. Cassell, M. Brunner, J. P. Allison. 1996. The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol. Rev. 153: 27-46. [Medline]
  54. Chen, W., W. Jin, S. M. Wahl. 1998. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor β (TGF-β) production by murine CD4+ T cells. J. Exp. Med. 188: 1849-1857. [Abstract/Free Full Text]
  55. Greenwald, R. J., M. A. Oosterwegel, D. van der Woude, A. Kubal, D. A. Mandelbrot, V. A. Boussiotis, A. H. Sharpe. 2002. CTLA-4 regulates cell cycle progression during a primary immune response. Eur. J. Immunol. 32: 366-373. [Medline]
  56. Boise, L. H., A. J. Minn, P. J. Noel, C. H. June, M. A. Accavitti, T. Lindsten, C. B. Thompson. 1995. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity 3: 87-98. [Medline]
  57. Jacob, J., R. Kassir, G. Kelsoe. 1991. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl: I. The architecture and dynamics of responding cell populations. J. Exp. Med. 173: 1165-1175. [Abstract/Free Full Text]
  58. Cozine, C. L., K. L. Wolniak, T. J. Waldschmidt. 2005. The primary germinal center response in mice. Curr. Opin. Immunol. 17: 298-302. [Medline]
  59. Sze, D. M., K. M. Toellner, C. Garcia de Vinuesa, D. R. Taylor, I. C. MacLennan. 2000. Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival. J. Exp. Med. 192: 813-821. [Abstract/Free Full Text]
  60. Ellyard, J. I., D. T. Avery, T. G. Phan, N. J. Hare, P. D. Hodgkin, S. G. Tangye. 2004. Antigen-selected, immunoglobulin-secreting cells persist in human spleen and bone marrow. Blood 103: 3805-3812. [Abstract/Free Full Text]
  61. Weller, S., M. C. Braun, B. K. Tan, A. Rosenwald, C. Cordier, M. E. Conley, A. Plebani, D. S. Kumararatne, D. Bonnet, O. Tournilhac, et al 2004. Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 104: 3647-3654. [Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
W. Stohl, N. Jacob, W. J. Quinn III, M. P. Cancro, H. Gao, C. Putterman, X. Gao, L. Pricop, and M. N. Koss
Global T Cell Dysregulation in Non-Autoimmune-Prone Mice Promotes Rapid Development of BAFF-Independent, Systemic Lupus Erythematosus-Like Autoimmunity
J. Immunol., July 1, 2008; 181(1): 833 - 841.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quandt, D.
Right arrow Articles by Brunner-Weinzierl, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quandt, D.
Right arrow Articles by Brunner-Weinzierl, M. C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS